Mucothiol «χωρίσ Ζάχαρη» (Carbocisteine)

Carbocisteine, the active ingredient in Mucothiol «χωρίσ Ζάχαρη», is a mucolytic presented as an oral formulation for oral use. It reduces the viscosity of respiratory tract mucus, facilitating clearance in patients with productive coughs associated with chronic bronchitis, COPD, and other respiratory conditions.

GNH USA supplies Mucothiol «χωρίσ Ζάχαρη», sourced from the EU, as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Carbocisteine is used to manage conditions characterized by thick, tenacious mucus in the respiratory tract.

Chronic bronchitis: improves mucus clearance and reduces cough frequency. COPD: thins airway secretions to aid expectoration. Acute bronchitis: facilitates removal of sputum and eases productive cough.

Carbocisteine may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Nausea: mild stomach upset often reported. - Vomiting: occasional episodes. - Diarrhea: loose stools. - Abdominal pain: discomfort in the stomach area. - Taste disturbance: altered taste perception. - Headache: mild headache.

Serious or Rare Side Effects: - Allergic reactions: rash, itching, or urticaria. - Angioedema: swelling of face, lips, or tongue. - Hepatic dysfunction: elevated liver enzymes. - Neutropenia: reduced white blood cell count.

When prescribing carbocisteine, several precautions should be considered to ensure safe use.

Pregnancy: safety not established; use only if potential benefit justifies the risk. Breastfeeding: unknown excretion; weigh benefits against possible infant exposure. Renal impairment: dosage may require adjustment in severe dysfunction. Asthma: monitor for possible bronchospasm, especially in sensitive individuals. Drug interactions: review concomitant mucolytics or antitussives for additive effects. Store at ambient temperature (below 25°C): keep in the original pack, protect from moisture.

Carbocisteine can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Co‑administration with other mucolytic agents (e.g., N‑acetylcysteine): may increase gastrointestinal irritation. - Use with strong antitussive preparations containing codeine: may counteract mucolytic action.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): monitor INR as theoretical bleeding risk may increase. - Antihistamines (e.g., diphenhydramine): observe for enhanced sedation. - Oral contraceptives: possible reduction in hormonal efficacy, monitor cycle. - Proton pump inhibitors: may alter absorption, watch for reduced effect.